Cargando…
Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma
Hepatocellular cancer (HCC) is currently the third leading cause of cancer death worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited efficacy, as the standard sy...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918266/ https://www.ncbi.nlm.nih.gov/pubmed/27508175 http://dx.doi.org/10.2147/JHC.S48958 |